Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 11/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 10/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696768 | 0.92 | HTR2C (0.45) | HTR2CSLC6A4SLC16A3SLC16A1HTR2A | |
| SCHEMBL3697267 | 0.92 | HTR2C (0.48) | HTR2CSLC6A4SLC16A3SLC16A1HTR2A | |
| SCHEMBL3703719 | 0.89 | HTR2C (0.43) | HTR2CSLC6A4HTR2A | |
| SCHEMBL3700534 | 0.88 | HTR2C (0.45) | HTR2CSLC6A4SLC16A3SLC16A1HTR2A | |
| SCHEMBL3703228 | 0.88 | HTR2C (0.45) | HTR2CSLC6A4SLC16A3SLC16A1HTR2A | |
| SCHEMBL3692811 | 0.88 | HTR2C (0.45) | HTR2CSLC6A4SLC16A3SLC16A1HTR2A | |
| SCHEMBL3701898 | 0.88 | HTR2C (0.49) | HTR2CSLC6A4SLC16A3SLC16A1HTR2A | |
| SCHEMBL3695135 | 0.88 | HTR2C (0.44) | HTR2CSLC6A4SLC16A3SLC16A1HTR2A | |
| SCHEMBL2838662 | 0.87 | SLC16A3 (0.38) | HTR2CSLC6A4SLC16A3SLC16A1 | |
| SCHEMBL3701837 | 0.86 | HTR2C (0.43) | HTR2CSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334301-B2 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20100210696-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210696-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | NPY4R, NPY5R, NPY1R | HTR2C 1425/4885SLC6A4 1108/4885SLC16A3 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.